Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 14, 2021, details a material modification to the rights of security holders for Allarity Therapeutics, Inc. The filing announces the creation of a new class of Series A Convertible Preferred Stock in connection with a pending Recapitalization Share Exchange and a Private Investment in Public Equity (PIPE) transaction. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- PIPE Investment: The Company entered into a Securities Purchase Agreement with 3i, LP for the purchase of 20,000 shares of Series A Convertible Preferred Stock at $1,000 per share, totaling $20 million.
- Warrant Issuance: Concurrent with the PIPE Investment, 3i, LP will receive a warrant to purchase up to an additional $20 million of common stock (approximately 2,018,958 shares) at an exercise price of $9.906 per share for a three-year term.
- Conversion Price: The initial fixed conversion price for the Preferred Stock is $9.906 per share, subject to a beneficial ownership limitation of 4.99% (adjustable to 9.99% with notice).
- Liquidation Preference: The preference is the greater of 125% of the conversion amount or the value upon immediate conversion, plus the Black Scholes Value of associated warrants.
- Financial Statements: This filing does not provide revenue, profit, cash flow, or debt metrics for the reporting period.
Material Changes and Transaction Status
The filing reports the filing of a Certificate of Designations for the Series A Preferred Stock. The closing of the PIPE Investment and the Recapitalization Share Exchange are conditioned on the effectiveness of the registration statement, the consummation of the share exchange, and the listing of shares on the Nasdaq Stock Market. These transactions are expected to close on or about December 20, 2021. The issuance of the Preferred Stock imposes restrictions on the Company's ability to declare dividends on or repurchase common stock if dividends on the Preferred Stock are not paid.
Outlook, Risks, and Unusual Items
- Anti-Dilution Protection: The Preferred Stock and Warrant include a "full ratchet" adjustment mechanism. If the Company issues new stock at a price lower than the conversion or exercise price, the price will be adjusted downward to the new issuance price.
- Redemption Triggers: The Company may be required to redeem the Preferred Stock for cash upon specific triggering events, including breaches of the Registration Rights Agreement, suspension of trading, failure to convert shares, or bankruptcy events.
- Liquidity Penalty: If the average daily dollar volume of the Company's stock is less than $2.5 million within 30 days of Nasdaq listing, the Preferred Stock is entitled to a one-time dividend increasing the stated value by 8% (to $1,080 per share).
- Volume Alternate Failure: If trading volume is less than $2 million within 30 days of listing, the conversion price may be adjusted to 80% of the average of the two lowest VWAPs in the preceding 10 days.
Investor Verification Checklist
- Verify the closing date of the Recapitalization Share Exchange and PIPE Investment (expected December 20, 2021).
- Confirm the listing of the PIPE Shares on the Nasdaq Stock Market.
- Review the full text of the Certificate of Designations (Exhibit 3.1) for specific definitions of "triggering events" and "Floor Price."
- Monitor the Company's daily trading volume to assess the risk of the 8% liquidity penalty dividend.
- Check for any subsequent filings regarding the effectiveness of the Form S-4 Registration Statement.